Glycorex Transplantation – removing antibodies from blood to improve transplantation and fight autoimmune diseases

Glycorex’s unique molecular level technology that specifically selects and removes antibodies in the blood has opened up ground-breaking treatments and solutions in healthcare. The company’s medical devices enable transplants across the blood groups saving lives and providing health economic benefits by increasing the number of transplants. The company’s technology to treat blood is applied in several health care settings and a new disruptive product has recently been launched with the potential to increase availability of blood plasma. Several new products for the treatment of autoimmune diseases are under development.

Glycorex Transplantation - removing antibodies from blood to improve transplantation and fight autoimmune diseases

In addition to kidney transplants, our product, Glycosorb® ABO, is used in several other types of transplants, such as liver, heart and stem cell transplants. More than 60 scientific papers with Glycosorb® ABO show excellent short- and long-term results fully comparable to blood group compatible transplants. Thanks to Glycosorb® ABO, blood group incompatible transplants are now routinely performed in many countries.

With our unique technology as a base, we are currently expanding into new interesting applications. In the area of transfusion medicine, we have recently launched a product intended to be used for donated plasma to produce universal blood plasma which can be given regardless of the recipient’s blood group, which means major improvements in logistics, safety and availability.
The focus of our development work is now to develop new treatments for severe autoimmune diseases. The closest to launch is a specific treatment for rheumatoid arthritis (RA) – a disease that has affected around five million people in Europe.

Glycorex Transplantation AB (publ) is based in Lund, Sweden, and its shares are listed on NGM – Main Regulated, Stockholm (NGM: GTAB B).

Glycorex Transplantation – removing antibodies from blood to improve transplantation and fight autoimmune diseases

More info : Glycorex Transplantation AB

Keywords : transplantation, autoimmune diseases, Rheumatoid Arthritis, antibodies hematology

IDD Biotech – differentiated therapeutic MAbs

IDD biotech aims to improve the life of patients by developing differentiated therapeutic MAbs for the pharmaceutical market with a pipeline of internally discovered product candidates and strategic collaborations with research institutes and pharmaceutical companies.

IDD Biotech – differentiated therapeutic MAbs

IDD Biotech

Continue reading

Swecure – immunoregulatory disorders

Swecure is a Swedish biotechnology company developing treatments for immunoregulatory disorders, such as allergy and IBD.

Swecure – immunoregulatory disorders

swecure AB

Continue reading

Medigene – personalized immunotherapies

Medigene is a biotech company focusing on the development of personalized T-cell immunotherapies. Medigene develops highly innovative treatment platforms concentrating on haematological malignancies, cancer and autoimmune diseases.

Medigene – personalized immunotherapies

medigene Continue reading

Selvita – accelerating drug discovery

Selvita is a biotech company offering drug discovery support at every step of the process, from the early discovery phase up to preclinical research. Selvita delivers a comprehensive panel of solutions to accelerate and decrease the cost of the introduction of new drugs to the market.

Selvita – accelerating drug discovery

selvita Continue reading

TxCell – antigen-specific Type 1 Treg cells

TxCell is a biotech company developing innovative and personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for autoimmune diseases and severe chronic inflammatory diseases.

TxCell – antigen-specific Type 1 Treg cells

txcell Continue reading

Zenith Epigenetics – bromodomain inhibitors

Zenith Epigenetics is a biotech company developing bromodomain (BET) inhibitors for the treatment of cancer and autoimmune disorders. Zenith Epigenetics aims to become a leading epigenetic company translating bromodomain biology into impactful therapies.

Zenith Epigenetics – bromodomain inhibitors

Zenith Epigenetics

Continue reading